Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 38

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 38
---
 Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (#) 
 (c)                                                                                                                                             |             |   |
|:-----------------------------------------------------------|:----|:--------------------------------------------------------------------------------------------------|----------:|:----|:--------------------------------------------------------------|-----:|:----|:------------------------------------------------------------------------------------------------------------------------------------------------|------------:|:--|
| 2013 Plan                                                  |     |                                                                                                   |   810,550 |     | $                                                             | 6.31 |     |                                                                                                                                                 |           - |   |
| 2018 Plan                                                  |     |                                                                                                   | 7,036,576 |     | $                                                             | 1.91 |     |                                                                                                                                                 | 2,068,226(1 | ) |
| Equity compensation plans not approved by security holders |     |                                                                                                   |         - |     |                                                               |    - |     |                                                                                                                                                 |           - |   |
| Total                                                      |     |                                                                                                   | 7,847,126 |     | $                                                             | 2.32 |     |                                                                                                                                                 |   2,068,226 |   |

| (1) | On January 1 of each calendar year, an additional number of Ordinary Shares equal to 5% of the total outstanding Ordinary Shares on such date (or any lower number of shares as determined by our Board) become available for issuance under 
 the 2018 Plan.                                                                                                                                                                                                                               |

Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 22 EXECUTIVE COMPENSATION Compensation Policy Our compensation policy was last ratified by our shareholders on July 31, 2024, after having been recommended by our Compensation Committee and approved by our Board. Under the Israeli Companies Law, our compensation policy must be re-approved, amended, or replaced by a new policy every three years. Although approval will not be required again until 2027, the Company has determined it is in its best interests to re-obtain approval of the compensation policy from the shareholders at the Annual Meeting, with amendments to certain thresholds to align with market standards and to attract prospective management members such that the policy would be effective for the next three years, or such longer period as permitted and in accordance with the Israeli Companies Law, and accordingly, we are presenting the Amended Compensation Policy to our shareholders for approval. See Proposal Five. The compensation policy and the Amended Compensation Policy include, among other matters prescribed by the Israeli Companies Law, a framework for establishing the terms of office and employment of the